Showing results (91-100 of 106) with videos related to

Sort By:
Pageof 11
Cancers|March 6, 2021
The Claudin-Low Subtype of High-Grade Serous Ovarian Carcinoma Exhibits Stem Cell FeaturesChiara Romani, Davide Capoferri, Elisabetta Grillo, et al.
Molecular Cancer Therapeutics|December 17, 2008
alphavbeta3 Integrin-dependent antiangiogenic activity of resveratrol stereoisomersMirella Belleri, Domenico Ribatti, Monica Savio, et al.
Oncotarget|July 19, 2016
Annexin 2A sustains glioblastoma cell dissemination and proliferationFrancesca Maule, Silvia Bresolin, Elena Rampazzo, et al.
Scientific Reports|December 2, 2016
Cellular aspartyl proteases promote the unconventional secretion of biologically active HIV-1 matrix protein p17Francesca Caccuri, Maria Luisa Iaria, Federica Campilongo, et al.
Blood|November 2, 2006
Bone morphogenic protein antagonist Drm/gremlin is a novel proangiogenic factorHelena Stabile, Stefania Mitola, Emanuela Moroni, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|March 31, 2015
Cavin-1 and Caveolin-1 are both required to support cell proliferation, migration and anchorage-independent cell growth in rhabdomyosarcomaFiorella Faggi, Nicola Chiarelli, Marina Colombi, et al.
Diabetologia|January 14, 2017
Inflammation and N-formyl peptide receptors mediate the angiogenic activity of human vitreous humour in proliferative diabetic retinopathySara Rezzola, Michela Corsini, Paola Chiodelli, et al.
Journal of Medicinal Chemistry|March 19, 2015
Design, synthesis, in vitro, and in vivo anticancer and antiangiogenic activity of novel 3-arylaminobenzofuran derivatives targeting the colchicine site on tubulinRomeo Romagnoli, Pier Giovanni Baraldi, Maria Kimatrai Salvador, et al.
Oncotarget|September 30, 2015
Evaluation of a novel human IgG1 anti-claudin3 antibody that specifically recognizes its aberrantly localized antigen in ovarian cancer cells and that is suitable for selective drug deliveryChiara Romani, Emiliano Cocco, Eliana Bignotti, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology|October 30, 2004
Antiangiogenic activity of semisynthetic biotechnological heparins: low-molecular-weight-sulfated Escherichia coli K5 polysaccharide derivatives as fibroblast growth factor antagonistsMarco Presta, Pasqua Oreste, Giorgio Zoppetti, et al.
Pageof 11